Clinical Research IO Revenue and Competitors
Estimated Revenue & Valuation
- Clinical Research IO's estimated annual revenue is currently $12.7M per year.
- Clinical Research IO's estimated revenue per employee is $140,000
- Clinical Research IO's total funding is $17.2M.
Employee Data
- Clinical Research IO has 91 Employees.
- Clinical Research IO grew their employee count by -9% last year.
Clinical Research IO's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Engineering | Reveal Email/Phone |
3 | Director, Corporate QA and Compliance | Reveal Email/Phone |
4 | Senior Director Customer Experience | Reveal Email/Phone |
5 | Senior Director Product Development | Reveal Email/Phone |
6 | Sr Director User Experience | Reveal Email/Phone |
7 | Customer Success Manager | Reveal Email/Phone |
8 | Study Design Manager | Reveal Email/Phone |
9 | Quality Control Manager II | Reveal Email/Phone |
10 | Marketing & Communications Manager | Reveal Email/Phone |
Clinical Research IO Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $668.1M | 3222 | 3% | $20M | N/A |
#2 | $5.3M | 46 | N/A | N/A | N/A |
#3 | $5.1M | 46 | -13% | $950K | N/A |
#4 | $1.7M | 23 | -4% | $30M | N/A |
#5 | $0.7M | 9 | N/A | N/A | N/A |
#6 | $0.7M | 9 | N/A | N/A | N/A |
#7 | $0.6M | 8 | N/A | N/A | N/A |
#8 | $2.5M | 25 | N/A | N/A | N/A |
#9 | $71M | 300 | -3% | N/A | N/A |
#10 | $14.2M | 98 | N/A | N/A | N/A |
#11 | $5060M | 7612 | -20% | $6.9M | $22.5B |
#12 | $53.7M | 302 | 7% | $8M | N/A |
#13 | $3.8M | 33 | N/A | N/A | N/A |
#14 | $4.2M | 21 | N/A | N/A | N/A |
#15 | $7.6M | 58 | 32% | N/A | N/A |
#16 | $25.7M | 161 | N/A | N/A | N/A |
#17 | $1167M | 5806 | N/A | N/A | N/A |
#18 | $16.5M | 82 | N/A | N/A | N/A |
#19 | N/A | 39 | N/A | N/A | N/A |
#20 | $1.7M | 24 | 4% | $5.1M | N/A |
What Is Clinical Research IO?
Clinical Research IO (CRIO) revolutionizes trial studies. We offer powerfully integrated eSource, CTMS, and stipend solutions—built for sites, by a site owner.\n\nOur software frees you from inefficient, error-prone binders because investigators can choose between tablets and desktop computers to capture source data. CRIO’s autofill and data validation tools reduce protocol deviations and save time. With patient scheduling, recruiting, and financial management, we provide you with an all-in-one enterprise solution.\n\nOur mission is to help you grow your business. We do that by streamlining your site’s operations, so that your studies don’t stop just because you aren’t in clinic. CRIO keeps your source data secure, so that you can access it anytime, anywhere.
keywords:saas
$17.2M
Total Funding
91
Number of Employees
$12.7M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Clinical Research IO News
An analysis of the HYVALUE trial, published in Circulation: ... participant attrition in the clinical trial, independent of race and gender.
For more information about CRIO, visit www.clinicalresearch.io. Stephen Boccardo, Senior VP of Sales Clinical Research IO (CRIO) +1 857-957-5376
BOSTON, April 5, 2022 /PRNewswire/ -- CRIO (Clinical Research IO), the leader in eSource technology, marks a noteworthy milestone,...
Clinical Research IO (CRIO), a Boston, MA-based technology firm offering clinical research sponsors and sites a platform to streamline clinical trials, closed a $3.5m Series A funding round. The round was led by Rally Ventures with participation from Raymond Chang, lead investor in the company’ ...
BOSTON, March 11, 2021 /PRNewswire/ -- Clinical Research IO (CRIO), a Boston-based technology firm offering clinical research sponsors and sites a platform to streamline clinical trials, announced the completion of a $3.5 million Series A round led by Rally Ventures. The round allows CRIO to ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.7M | 91 | -13% | $1.3M |
#2 | $19.1M | 91 | -21% | N/A |
#3 | $20.7M | 91 | 3% | N/A |
#4 | $7.5M | 91 | -1% | N/A |
#5 | $8.8M | 91 | 3% | N/A |